The aim was to explore the frequency of genetic and other medical conditions, including epilepsy, in a population-based group of 208 preschool children with early diagnosis of Autism spectrum disorders (ASD) and to relate outcome at a 2-year follow-up to the co-existing medical findings. They had all received early intervention. The Vineland Adaptive Behaviour Scales (VABS-II) composite score served as the primary outcome measure. In the total group, 38/208 children (18 %) had a significant medical or genetic condition. Epilepsy was present in 6.3 % at the first assessment and in 8.6 % at follow-up and was associated with more severe intellectual impairment. A history of regression was reported in 22 %. Children with any medical/genetic condition, including epilepsy, as well as children with a history of regression had significantly lower VABS-II scores at the 2-year follow-up. Children with a medical/genetic condition, including epilepsy, had been diagnosed with ASD at an earlier age than those without such conditions, and early age at diagnosis also correlated negatively with adaptive functioning outcome. The results underscore the importance of considering medical/genetic aspects in all young children with ASD and the requirement to individualize and tailor interventions according to their specific needs.
Introduction
The aim of the present study was to explore the frequency of genetic and other medical conditions, including epilepsy, in a representative group of preschool children with early diagnosis of Autism Spectrum Disorders (ASD) and to relate outcome to co-existing medical findings.
According to several studies, early intervention has been reported to improve outcome in children with ASD [14, 22] . However, these studies have demonstrated considerable variability in outcome with low initial IQ repeatedly demonstrated to contribute to a less favourable outcome [23] . It is important to remember that in many of these studies children with co-existing genetic and medical disorders, such as epilepsy, have been excluded [12, 14, 23, 48] .
Autism spectrum disorders are highly heritable neurodevelopmental disorders affecting about 1 % of the childhood population [6, 18] . The etiological heterogeneity in ASD is extensive. In about 10-20 % of all ASD cases, a genetic cause is identified [1, 10] . More than 100 disease genes have been reported in individuals with ASD [9] .
In children with ASD conventional karyotyping identifies abnormalities in about 2 % [42] and Fragile X syndrome is identified in about 2 % [38] . With the use of whole genome array-based comparative genomic hybridization (array-CGH), sub-microscopic deletions and duplications (copy number variations; CNVs) have been increasingly identified in ASD as well as in intellectual disability (ID) [32] and epilepsy [30] . In children with ASD, about 7 % have been reported to have causative CNVs [41, 45] .
Autistic features or ASD and/or epilepsy occur in several well-recognized single-gene disorders such as Tuberous sclerosis, Rett syndrome, Fragile X, Smith-LemliOpitz and Angelman syndrome [10] . Although genetic susceptibility is of major importance, environmental and epigenetic factors may influence the risk of ASD. The (relatively small) discordance in monozygotic twins suggests the presence of non-heritable, pre-and perinatal risk factors for autism [26, 39] .
Several prenatal and perinatal risk factors have been associated with ASD. Intrauterine congenital central nervous system viral infections and exposure to various agents such as sodium valproate may increase the risk for cognitive impairment, including ASD [15, 33, 37] . Epidemiological studies have not yet found any association between alcohol consumption and increased risk for ASD [21] , but in two Swedish studies, 9-13 % of children whose mothers abused alcohol in pregnancy had ASD [4, 27] . Regarding perinatal factors, several studies have shown increased risk for cognitive problems, including ASD in extremely preterm and low birth weight children [13, 24, 29] .
The prevalence of epilepsy in childhood in general is 0.5-0.7 %. Epilepsy, much like ASD, can be viewed as a spectrum disorder with multiple aetiologies and highly variable clinical presentation [25] . Cognitive deficits are prevalent in children with epilepsy with approximately 25 % having mental retardation [7] . The prevalence estimates of epilepsy in children with ASD vary from 5 to 46 % [43, 46] . The rates of epilepsy in ASD increase with age and the association between ASD and epilepsy is closely linked to the presence and degree of cognitive impairment. In a meta-analysis by Amiet et al. [3] , a pooled frequency of epilepsy was 21.4 % in patients with autism. The rate of epilepsy in subjects without cognitive impairment was 8 %, clearly a higher prevalence than in the normal population. In children with intellectual disability and active epilepsy co-existing ASD is found in 37 % [44] . It is well established that early onset epilepsy increases the risk of ASD. Saemundsen [40] found that 14 % of children with epilepsy onset in the first year of life developed autism. In children with infantile spasms, the risk for ASD was 46 % and in children with more severe structural brain disorder (hypoxic ischemic encephalopathy, cortical dysplasia, tuberous sclerosis) 69 % were found to have ASD. The author's conclusion was that the risk of developing autism is probably mostly predicted by the origin of the seizures and, usually, not a consequence of an epileptic encephalopathy.
Developmental regression with loss of acquired skills is reported in children with ASD at rates ranging from 15 to 40 % depending on the definition of regression and sample of children [28, 31] . The most consistent documented finding in such cases is loss of verbal skills, but this is often accompanied or preceded by loss of social skills. The onset of regression is often reported to be between the ages of 15 and 24 months. Previous studies have not found epilepsy, seizures or subclinical EEG abnormalities to be more prevalent in children with ''autistic regression'' compared to non-regressive autism [5, 19] . Children with autistic regression tend to have poorer cognitive outcome compared to children without regression [8] . In a subset of children with regressive autism, early development may be delayed and some children have social deficits before the regression is identified [35] . To our knowledge, no previous study has explored the influence of co-occurring medical conditions or a history of developmental regression in relation to early intervention.
Method

Participants
The study included 208 children, 20-54-month-old, when referred to a specialized habilitation centre with a diagnosis of ASD. They were drawn from a population-based group of 313 children (born 2002-2006) with ASD diagnoses in Stockholm County, a region with approximately 28,000 births per year. Of these 313 children, 288 had been referred for early intervention to a specialized habilitation centre for preschool children with ASD. Twenty-five children with more severe medical conditions and syndromes in combination with ASD were referred to general habilitation centres due to more complex needs. At these centres, no specific ASD interventions were provided. This group was not included in the outcome study.
Of the 288 children, 24 had been referred to the centre prior to study start and could not be included. Of the remaining 264 children, 37 families declined participation, 15 families could not communicate in either Swedish or English, two children moved abroad and another two were referred back to general habilitation centres because they had complex medical needs. This means that 208 children (176 boys and 32 girls) were included in this prospective two-year follow-up study (Fig. 1) . No exclusion of children with ASD and identified medical conditions/or significant ID was done once type of intervention had been initiated. However, it is clear that the study group did not include some of the most medically ''complex'' cases with ASD in the population.
Of the total group, 64 (31 %) had been referred before the age of 36 months, 83 (40 %) between 37-48 months and 61 (29 %) between the ages of 49-54 months.
Of the 208 children, 198 participated in the two-year follow-up. Complete cognitive data was obtained in 196, and data regarding type of ASD diagnosis was obtained in 197 [17] . Autistic disorder/childhood autism was diagnosed in 105 (53 %), atypical autism in 58 (29 %), Asperger syndrome in 13 (7 %), and autistic traits in 21 (10 %) at follow-up after 2 years. Four of those with autistic traits (2 % of the total group) had ID with autistic traits and 17 (8 %) had attention/language impairment with autistic traits. Of the 196 children, 95 (48 %) had ID (IQ \70), 50 (26 %) had low normal/borderline intellectual function (IQ 70-84), and 51 (26 %) average or above average intellectual level (IQ C85). In 12 children with incomplete cognitive assessment at the follow-up, the cognitive level was classified according the level defined at referral (5 children with ID, 5 with developmental delay/borderline IQ and 2 with average intellectual level).
Measures
At referral to the habilitation centre, Time 1 (T1), data were collected from each child's maternity and obstetric care units, the Child Health Care centre (CHC) and all hospital and outpatient clinics attended by the child. Both at T1 and at the two-year follow-up, Time 2 (T2) the paediatrician/ child psychiatrist in the research team examined all children. Details regarding interview protocols, including cognitive assessments and questionnaires at T1 and T2 have been reported in previous publications [16, 17] .
In addition to data from records, parents were interviewed regarding the child's pre-and perinatal history, early development, and any genetic, neurologic or other clinically significant medical condition, including epilepsy.
Regression was defined as loss of more than five spoken words used communicatively in children more than 15 months of age. In children younger than 15 months, regression was determined when there was a clear indication of loss of social interest and contact. Parents were interviewed (in close temporal connection to the first diagnostic assessment) regarding a history of regression in the child and this information was compared to available data in CHC and medical records. Consistency was required between parental information and the notes in the record's from CHC. Participating families were recommended genetic testing using array-based Comparative Genomic Hybridization (array-CGH) (these findings will be described in detail in a forthcoming paper) and testing for Fragile X. Conventional chromosomal karyotyping had been performed in many children. In girls with a clinical suspicion of Rett syndrome mutation for MECP2 were analysed.
Medical and genetic conditions were defined as: (1) a significant intrauterine harmful exposure, (2) substantial prematurity (gestational age less than 29 weeks), (3) an identified genetic disorder including significant genomic imbalances identified with array CGH, (4) abnormal brain MRI findings and (5) a clinical diagnosis of epilepsy.
At T2, the parents of 198 children were interviewed a second time to collect information about any new medical condition that had affected the child during the observation time and 208 hospital and outpatient medical records were once again reviewed. At that time, a new cognitive assessment was carried out to establish the child's Developmental Quotient/Intelligence Quotient (DQ).
Intervention
All 208 children received intervention based on principles of Applied Behaviour Analysis (ABA). The study design was naturalistic. There was no randomization to treatment type. Parental preference was the most decisive factor. The presence of medical/genetic condition did not affect choice of intervention type. In many children, a medical condition had not yet been identified. One group (n = 93) received ''intensive'' and the remainder (n = 105) ''non-intensive'' targeted intervention. The different levels of interventions were defined as: Intensive intervention based on ABA, i.e., early intensive behavioral intervention (EIBI), given at the preschool and by the parents at home with assistance from the center, with the intention to treat (a) 15 h or (b) 25-30 h per week or 30-40 h per week. Non-intensive targeted intervention based on ABA, consisting of different targeted types of training (toilet training, speech and language training, training of compliance or other specific training that the child was deemed to need). Details of these interventions have been reported in a previous paper [17] .
Outcome measure
The primary outcome measure was change in Vineland Adaptive Behaviour Scale (VABS-II) composite scores between T1 and T2. VABS II is a valid and often used outcome measure of adaptive skills in children with ASD [14, 20] . A total of 192 children had complete VABS-II scores both at T1 and T2. Numbers of children in the outcome analyses reflect the number of individuals that could be assessed according to the studied variable and to the Vineland change score. Outcome was measured by raters who were blind to the type of intervention given.
Statistical analyses
Data analysis were conducted with the IBM Statistical Package for the Social Sciences (SPSS) Version 19. In order to examine the influence of potential dichotomous risk factors (e.g. gender) on various dichotomous conditions (e.g. a medical/genetic condition), odds ratios (OR) and their 95 % confidence intervals (95 % CI) were calculated by logistic regression analysis. Mean age at referral for intervention for children with versus for children without medical/genetic conditions was compared with a t test.
Vineland Adaptive Behaviour Scales change scores were related to (1) any medical/genetic condition including epilepsy, (2) epilepsy ''only'', (3) regression and (4) age at referral, and for each of these four factors also to the level of intensity of intervention. For each factor, a 2 (T1/ T2) 9 2 (level of intensity of intervention) 9 2 (value on current factor, e.g. regression Yes/No) mixed Analysis of Variances (ANOVA) was computed, using eta-squared (g 2 ) as a measure of effect size.
An alpha level of 0.05 was used for all statistical analyses.
Ethics
The Regional Ethics Committee in Stockholm approved the study.
Results
Medical/genetic conditions, including epilepsy, in preschool children with ASD At T1, a medical/genetic condition with probable association with the child's ASD was identified in 22 children (11 %), and at T2 another 16 children had been found to have an associated medical/genetic condition (38/208) (18 %).
At T1, 7 of the 208 children had a medical disorder/ genetic syndrome identified. Of these, three boys had tuberous sclerosis (all with epilepsy), one boy had Fragile X syndrome (141/142 FMR1-examined children tested negative for Fragile X), one boy had pyridoxine dependency (with a verified mutation in the ALDH7A1-gene), one boy had duplication 17p 13.3, and one girl had deletion 22q11 syndrome. Another nine children had medical conditions with less clear (but probable) association with the child's ASD. Of these nine, three had abnormal magnetic resonance imaging findings indicating cortical dysplasia/migrational disorder, two had been born preterm (gestational week 24 and 28), one adopted child met criteria for foetal alcohol spectrum disorder, one child had a history of prenatal intrauterine exposure to sodium valproate (mother treated for epilepsy), one boy had congenital hydrocephalus with ventriculoperitoneal shunt, and one boy was clinically diagnosed with Pierre Robin syndrome. Epilepsy without aetiology was found in another six children (all male) at T1.
At T2, medical/genetic conditions could be analysed in the total group of 208 children. Five children developed epilepsy between T1 and T2. Two of the three girls clinically suspected of having Rett syndrome were ''confirmed'' by genetic testing for MECP2 mutation. In another nine children, analysed with array-CGH, a significant genomic imbalance was found. Details on these findings and associated developmental profiles in children with abnormal CGH-array results will be presented in a separate article. The preliminary diagnostic yield was 7.4 % (12/162).
ID was found in 63 % (24/38) of those with medical/ genetic/epilepsy disorders as compared with 45 % (76/170) in those without such disorders (OR = 2.12, 95 % CI = 1.03-4.38, p = 0.042).
Medical/genetic conditions including epilepsy were more often, but not significantly, found in children with the combination of ASD and ID (24/102) (24 %) as compared with those who had ASD without ID (14/106) (13 %) (OR = 2.0 95 % CI = 0.98-4.17, p = 0.057).
Of the 32 girls, 10 (31 %) had an identified medical/ genetic condition. The corresponding rate in boys was 28/176 = 16 % (OR = 2.40, 95 % CI = 1.03-5.62, p = 0.043).
Any medical/genetic condition including epilepsy and age at referral Children with medical/genetic conditions, including epilepsy, had been referred for intervention at significantly earlier ages compared to those without such conditions (M = 38.3, SD = 10.1 vs. M = 41.4, SD = 8.3; t 206 = 1.97, p = . 05).
Epilepsy
At T1, 13/208 (6 %) children had been diagnosed with epilepsy and at T2 (ages between 4.5 and 6.5 years) 18/208 (9 %) had epilepsy. Excluding those children whose epilepsy was part of a known medical/genetic syndrome, the epilepsy prevalence was 5 % (''idiopathic epilepsy'').
Epilepsy onset varied from the first days of life up to the age of 6 years. Four children (4 boys) had infantile spasms (West syndrome), of whom two had tuberous sclerosis, one had a CNS-malformation, and one was ''idiopathic''. A definite aetiology was identified in 7/18 cases with epilepsy; three children had tuberous sclerosis, two had CNS malformations, one boy had B6 dependency, and one girl had Rett syndrome. Of the 11 children without an identified medical disorder/genetic syndrome and with normal magnetic resonance imaging, 6 could be classified as having epilepsy with generalized seizures, 2 had focal seizures and 3 had unclassifiable seizures. Epilepsy was diagnosed in 4/32 girls (13 %) and in 14/176 boys (8 %), (OR = 1.65, 95 % CI = 0.51-5.39, n.s.). In children with the combination of ASD and ID (IQ \70) 13/102 (13 %) had epilepsy whereas children with ASD and borderline, average or above average IQ (IQ [70), 5/106 (5 %) had epilepsy (OR = 2.95, 95 % CI = 1.01-8.60; p = 0.047).
Clinical characteristics of children with epilepsy are presented in Table 1 .
Regression and clinical characteristics
A history of regression was described both in the child's CHC records and at parental interview in 46/208 children (22 %). The most consistent finding was loss of expressive language skills. A few children were also reported to have deterioration in social interaction skills and some behavioural changes such as hyperactivity or extreme passivity. Regression was reported in 5/32 girls (16 %) and 41/176 boys (23 %), (OR = 0.61, 95 % CI = 0.22-1.68, n.s.).
A history of regression was more common in children with a clinical diagnosis of autistic disorder (33/105, 31 %) as compared with children with atypical autism/PDD-NOS (7/ 58, 12 %, OR = 3.34, 95 % CI = 1.37-8.14, p = 0.008).
In children with the combination of ASD and ID, regression was reported in 34 % (35/102) versus 10 % (11/ 106) in children with ASD without ID (OR = 4.51 95 % CI = 2.14-9.51, p \ 0.001).
Regression and relation to epilepsy (including febrile seizures)
Epilepsy was no more common in children with regression Outcome in relation to medical/genetic conditions, excluding epilepsy, and to intensity of intervention As shown in Fig. 2 , children without any medical/genetic condition had a positive VABS-II change score at T2 (compared to T1) whereas children with a medical/genetic condition (excluding epilepsy) had a negative change score. A 2 9 2 9 2 mixed ANOVA with Medical/genetic condition (yes, no) and Intervention intensity (intensive or non-intensive ABA) as between-subjects factors, Time (T1, T2) as a within-subjects factor and Vineland composite score as the dependent variable showed however that the Outcome in relation to epilepsy and to intensity of intervention A 2 9 2 9 2 mixed ANOVA with Epilepsy (yes, no) and Intervention intensity (intensive or non-intensive ABA) as between-subjects factors, Time (T1, T2) as a within-subjects factor and Vineland composite score as the dependent variable revealed a significant Epilepsy 9 Time interaction effect (F 1,188 = 7.09, p = . 008, g 2 = . 036). As shown in Fig. 3 , children without epilepsy had a positive VABS-II change score at T2 (compared to T1) whereas children with epilepsy had a negative change score (p \ . 01).
Outcome in relation to regression and to intensity of intervention A 2 9 2 9 2 mixed ANOVA with Regression (yes, no) and Intervention intensity (intensive or non-intensive ABA) as between-subjects factors, Time (T1, T2) as a within-subjects factor and Vineland composite score as the dependent variable revealed a significant Regression 9 Time interaction effect (F 1,188 = 4.58, p = 0.034, g 2 = 0.024). As shown in Fig. 4 , children without regression had a positive VABS-II change score at T2 (compared to T1) whereas children with regression had a negative change score. We also obtained a main effect of regression. Children without regression had a significantly higher mean Vineland composite score (irrespective of time) than children with regression (F 1,188 = 11.90, p \ 0.001, g 2 = 0.060).
Outcome in relation to age at referral and to intensity of intervention A 2 9 2 9 2 mixed ANOVA with referral age (before or after the age of 3 years) and Intervention type (intensive or non-intensive ABA) as between-subjects factors, Time (T1, T2) as a within-subjects factor and Vineland composite score as the dependent variable revealed a significant referral age 9 time interaction effect (F 1,188 = 8.32, p = 0.004, g 2 = 0.042). As shown in Fig. 5 , children who had been referred after the age of 3 years had increased their VABS-II composite score at T2 (compared to T1) whereas children who had been referred before the age of 3 years had decreased their score [48] . 
Discussion
The major findings of the present study were that (1) a medical/genetic disorder, including epilepsy, had been identified in 18 % of these preschool children-and in 24 % of those with ASD plus ID at follow-up-and the rate of such disorders increased over the two-year study period, (2) about one in five of the children with ASD had a clear history of regression, (3) about one-third of the sample was referred for intervention before 3 years of age, and that (4) all of these ''background factors'' contributed to more negative VABS-II outcomes, irrespective of intervention intensity. The study presents data from a relatively large population-based group of children with ASDs with a variety of ASD aetiologies represented. During the 2-year follow-up period all had received intervention, either intensive or targeted, non-intensive, based on ABA. Parents and preschool staff of all children had received information about the basic principles of ABA, to use in everyday situations together with the child [17] .
In a recent systematic review of early intensive intervention, the authors concluded that some children with ASDs who enter early intensive behavioural and developmental interventions show improvements in cognitive performance, language skills and adaptive behaviour skills when compared with eclectic treatments [48] . However, ''across the available literature many children who receive early intervention will not demonstrate dramatic gains in social, cognitive, adaptive and educational functioning'' [48] .
In the study by Dawson et al. [12] significant gains were demonstrated as to cognitive and adaptive behaviour.
However, in this ''Early Start Denver Model'' children with identified medical disorders and those with IQs below 35 were excluded.
Our study group varied with respect to ASD severity and intellectual level and no exclusion from intervention had been made because of any specific medical disorder, even though a subgroup with medical disorders/genetic syndromes involved in ''regular habilitation programmes'' had not been included in the study. Moreover, there had been no randomization to treatment groups. The study design was, in effect, naturalistic.
A heterogeneous spectrum of aetiologies and co-existing disorders related to autism was found, representing several distinct categories; central nervous system malformations, genetic syndromes, single gene disorders, significant genomic imbalances and prenatal acquired disorders. Thus, an important subgroup of children with an early ASD diagnosis has identifiable medical/genetic disorders, including epilepsy, and these children more often have low cognitive functioning.
The rate of epilepsy increased from 6.3 % in children aged younger than 4.5 years to 8.6 % at the 2-year followup, and is expected to increase further over time [11] . Epilepsy was more often found in children with ASD and associated ID. The epilepsy prevalence in children with ''idiopathic autism'' at age below 6.5 years was 5.3 %, clearly very much higher than in the general population (Stockholm County age 1-6 years; 0.6 %. (pers. comm. Per Amark 2012, [2] . In children with epilepsy, the outcome results may to some extent be affected by incomplete seizure control, even though this was not an obvious finding in the present study. Also, at least hypothetically, antiepileptic treatment may carry a risk for negative cognitive side effects, but this was not examined specifically in the present study. There was also a very high rate of febrile seizures in the ASD group. It is possible that the seizures in this subgroup should be seen as an indication of a more general brain problem rather than as a factor contributing to the pathogenesis in itself [34] .
Children with ASD and regression significantly more often had a more severe ASD type and more often ID compared to those without regression. We found no support for an association between regression and epilepsy in our sample. Such an association has often been suggested. However, the relationship between autistic regression and epilepsy remains controversial [36, 47] .
There was an association between age at referral and coexisting medical disorders. Children with a medical diagnosis had been referred at a significantly earlier age compared with those without an identified medical disorder. Thus, there is reason to believe that children identified with ASD at a low age will have an increased risk of having cooccurring intellectual disability, genetic and medical conditions reflecting an apparent and more severe underlying brain dysfunction compared to children diagnosed at higher ages, with more often milder forms of ASD, including Asperger syndrome.
This observation highlights the necessity of having a structured follow-up of all children with diagnosed ASD in order to catch additional disorders that evolve over time and accordingly to be able to adapt services. Besides, during our study period the genetic technology to analyse submicroscopic genomic imbalances improved and our study group included those with abnormal CGH-array [42] . Hence, many children could receive a medical aetiological diagnosis at follow-up.
Conclusions and clinical considerations
This study had a naturalistic design. Pre-school children with different types and severities of ASD, referred to a specialized habilitation centre for early intervention were included regardless of co-existing medical condition. A comprehensive medical assessment including genetic testing (array-CGH, Fragile X and Rett syndrome) was performed during the study period. The interpretation of our results has to take these circumstances into account. It should also be taken into account that a large number of significance tests were performed. Significant differences should therefore be interpreted with the problem of mass significance in mind. On the other hand, some of the nonsignificant differences could be due to low statistical power because of small n's. The outcome variable was change in VABS-II composite scores. Some ASD intervention studies also present changes in raw and standard scores. Individual improvements may not be reflected by the age normed composite scores.
In this study, we found that the presence of identified medical/genetic conditions, including epilepsy, exhibited a poorer outcome as compared to children without such disorders. A developmental trajectory with regression was also negatively associated with outcome. Children, referred before age 3 years displayed a poorer outcome compared to those referred after this age. This group had significantly more co-existing medical conditions. The results underscore the importance of considering medical/genetic aspects in all young children with ASD-even in those not considered to have extremely complex medical needs-and the requirement to individualize and tailor interventions in accordance with the large clinical variation that characterize this group of children with ASD.
